Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Contributed by: Business Wire

Logo

Tags

Technology

Research

Clinical Trials

Biometrics

Health

Pharmaceutical

Science

Artificial Intelligence

Oncology

science

More Like This

EP2_4 Receptor (Photo: Business Wire)

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

Owkin Launches ATLANTIS: An Extensive Multimodal Patient Data Discovery Program Across 7 Countries in 11 Therapeutic Areas

K Navigator home screen.

Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x

Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer

Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare

PR Newswire associated0

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology